zoledronic acid / Generic mfg. - LARVOL DELTA

Validation of a bone metastasis technology platform against clinically used standard-of-care therapies (AACR 2026) - "SOC treatments included doxorubicin (4 mg/kg, ip, BIW) in the TNBC model, docetaxel (10 mg/kg, ip, BIW) in the CRPC model, bortezomib (0.5 mg/kg, ip, BIW) in the MM model, and zoledronic acid (0.1 mg/kg, QW) in all models as an inhibitor of cancer-induced bone loss.In the TNBC model, doxorubicin decreased tumor growth and both doxorubicin and zoledronic acid decreased bone loss. In the MM model, bortezomib decreased tumor growth and zoledronic acid decreased bone loss.These results demonstrate that BMTP shows the same clinical features and responses to therapies that are observed in patients with TNBC, CRPC and MM. We conclude that BMTP is a clinically relevant translational tool for evaluating efficacy of cancer therapies on bone metastasizing cancers."

Clinical • Breast Cancer • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor • Triple Negative Breast Cancer

A tumor-derived PTHrP-calcium axis drives cardiac dysfunction to connect cancer cachexia with mortality (AACR 2026) - "To investigate whether hypercalcemia was a driver of cachexia-associated cardiac dysfunction, we pharmacologically suppressed calcium levels with continuously infused zoledronic acid (ZA)...Taken together, these preclinical data demonstrate that tumor-derived PTHrP plays a major role in driving cachexia and associated cardiac dysfunction in the C26 model, and that cardiac dysfunction may be a final common pathway of mortality in CC. Our findings raise the possibility that PTHrP-driven cachexia may be a biologically distinct and therapeutically relevant subgroup of cancer cachexia."

Oncology

Fanconi syndrome induced by zoledronic acid: Two case reports. (PubMed, Medicine (Baltimore)) - "These cases highlight the importance of early recognition and close monitoring of renal tubular function in patients receiving ZA. Screening for FS, including urinalysis, blood gas analysis, and serum electrolytes, should be considered within the first month of therapy and repeated regularly thereafter. Clinicians should maintain high vigilance for FS, especially when ZA is used concurrently with other nephrotoxic agents such as adefovir."

Journal • Genito-urinary Cancer • Hepatitis B • Infectious Disease • Metabolic Disorders • Nephrology • Oncology • Prostate Cancer • Renal Disease • Solid Tumor

The Complex of Copper (II) and Zoledronic Acid: Relevance to Oxidative Death of Leukemia Cells in the Bone Marrow. (PubMed, Int J Mol Sci) - "Importantly, the K562 chronic myelogenous leukemia cells that demonstrated an attenuated response to the 3d generation Bcr-Abl tyrosine kinase inhibitor in the medium conditioned by bone marrow-derived fibroblasts, were readily killed by CuZA-cysteine combination. Thus, oxidative burst upon metal reduction in CuZA complexes emerges as a promising method of eradication of tumor cells in the bone microenvironment."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR

Calcium Phosphate Bone Substitutes in the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Review. (PubMed, J Funct Biomater) - "This review examines the underlying mechanisms of this preventive therapeutic strategy and evaluates studies investigating synthetic calcium phosphate biomaterials for BRONJ prevention through zoledronate adsorption at jaw wound sites, thereby reducing soft tissue toxicity and promoting healing. The evidence supports the protective effect of these biomaterials as a scientifically grounded preventive approach for BRONJ."

Journal • Review • Pain

Inhibiting CDK9/13 decreases progression of multiple myeloma and myeloma-induced bone disease in preclinical studies (AACR 2026) - "OBP-004 showed significantly stronger tumor growth inhibition than bortezomib and decreased cancer-induced bone loss similarly to zoledronic acid.We conclude that CDK9/CDK13 is a potential target in hematological malignancies including MM. By targeting CDK9/13, it is possible to affect both tumor growth and cancer-induced bone loss."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Solid Tumor • CDK13 • CDK9

From animals to computational oncology: Digital twins as ethical enablers of next-generation bone metastasis research (AACR 2026) - "We further conducted robust double verification by simulating both the anti-angiogenic effects of cabozantinib and the anti-resorptive effects of zoledronic acid...Computational compression tests revealed increased fragility in trabecular bone following treatment with the bone-targeting agent Radium-223, whereas three-point bending tests showed no fragility in cortical bone post-treatment...Overall, our digital twin approach provides a transformative platform to dissect tumor progression, predict therapy response, and evaluate the consequences on bone mechanics. By enabling these insights in silico, we aim to significantly reduce dependence on animal models, directly supporting and strengthening the 3Rs principle."

Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Timing of dental surgery in patients receiving bone-modifying agents: Medication related osteonecrosis of jaw (MRONJ) and implant outcomes in a cohort of 5,284 oncology patients within an integrated dental pathway. (PubMed, J Clin Exp Dent) - "BMAs included intravenous zoledronic acid (n=4,087), subcutaneous denosumab (n=1,187) and oral alendronate (n=10). Dental surgery during or after BMA therapy, even with planned drug holidays, was associated with higher MRONJ and implant loss. Early dental referral and a cautious approach to elective implants after BMA initiation should be standard in oncology supportive care."

Journal • Review • Breast Cancer • Genito-urinary Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation

INCIDENCE, RISK FACTORS AND OUTCOMES OF AVASCULAR NECROSIS IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS DEVELOPING GRAFT-VERSUS-HOST DISEASE (EBMT 2026) - "All patients had hip involvement with median ARCO stage II; 4 had shoulder and 1 had wrist involvement(median number of joints involved: 2,range:1-4).Twelve AVN patients required vitamin D supplementation at diagnosis of AVN, and 13 received bisphosphonates(alendronate:11, zoledronate:2)...AVN cases received higher starting dose of systemic steroids for acute GVHD(median:2.19 vs 1.19 mg/kg prednisolone equivalents, p=0.016), but there were no differences in steroid therapy duration, steroid-refractoriness, or use of maintenance prednisolone and oral budesonide... Symptomatic AVN incidence among ASCT recipients who developed GVHD was 6.4%, with 57% requiring surgery. Higher pre-ASCT steroid exposure, higher initial steroid dose for acute GVHD, higher CD3+ cell dose, and pre-ASCT vitamin D deficiency were potentially modifiable risk factors for AVN."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Lymphoma • Orthopedics • Transplantation

Cervical Lymphadenopathy as Initial Presentation of Foamy Gland Adenocarcinoma of the Prostate: A Case Report. (PubMed, Onco Targets Ther) - "Following the diagnosis, the patient received conservative management with androgen deprivation therapy (bicalutamide and goserelin) and zoledronic acid. Unfortunately, he passed away 9 months later due to a COVID-19 infection. We present this rare variant of PCa metastasis to attract the attention of clinicians and pathologists."

Journal • Genito-urinary Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

A CASE OF PRIMARY HYPERPARATHYROIDISM IN WHICH CALCIMIMETICS WAS INEFFECTIVE BUT BISPHOSPHONATE ALONE WAS EFFECTIVE (ISN-WCN 2026) - "Treatment with both zoledronic acid (4 mg intravenously) and the calcimimetic agent evocalcet (1 mg/day) was started to control severe, refractory hypercalcemia. She was discharged on hospital day 21.Conclusion What was most remarkable about this case was that, on the morning of surgery, the serum iPTH level had further increased to 3880 pg/mL despite evocalcet treatment, which is indicated for primary hyperparathyroidism. The negative feedback mechanism via the calcium-sensing receptor was presumed to have failed, and only the bisphosphonate therapy proved effective.In conclusion, in cases of extreme and refractory hypercalcemia due to markedly elevated iPTH, there may be instances in which calcimimetics are ineffective, whereas bisphosphonate therapy alone is highly effective."

Clinical • Acute Kidney Injury • Anorexia • Endocrine Disorders • Metabolic Disorders • Nephrology • COL1A2 • TRAP

Digitally enhanced fracture liaison service in Austria-a feasibility analysis. (PubMed, Arch Osteoporos) - "Implementation of a digitally integrated FLS in routine inpatient care is feasible and enables structured identification, assessment, and treatment recommendation for patients with fragility fractures. However, limited staffing resources and challenges in post-discharge therapy implementation highlight the need for dedicated personnel and improved cross-sectoral care pathways."

Journal • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Preventive care • Rheumatology

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (PubMed, Ann Oncol) - "PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis."

Journal • Cardiovascular • Castration-Resistant Prostate Cancer • Fatigue • Genito-urinary Cancer • Hematological Disorders • Hypertension • Musculoskeletal Diseases • Neutropenia • Oncology • Pain • Prostate Cancer • Solid Tumor

Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial. (PubMed, Br J Cancer) - P3 | "Adding zoledronic acid did not improve clinical outcomes in ES."

Journal • P3 data • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor

Case report of severe hypocalcemia with atypical symptoms after zoledronic acid in palliative care: a deprescribing pitfall. (PubMed, BMC Palliat Care) - No abstract available

Journal • Endocrine Disorders • Palliative care

Double-edged-sword effect of bisphosphonates on the osteogenic differentiation of human periodontal ligament stem cells. (PubMed, Front Pharmacol) - "In this study, human PDLSCs were exposed to graded concentrations of zoledronate (ZOL, 0.01-10 μM) to characterize dose-dependent effects on cell viability, apoptosis, and osteogenic differentiation...These findings demonstrate a double-edged-sword effect of BPs on PDLSCs: low-dose ZOL enhances osteogenesis through coordinated activation of Wnt/β-catenin and MAPK pathways, whereas high-dose exposure is cytotoxic and suppresses regenerative potential. The results underscore the necessity of precise BP dose control to maximize periodontal regeneration while minimizing MRONJ risk."

Journal • Oncology • Rheumatology • Solid Tumor

LRP5-related primary osteoporosis: phenotypic spectrum and treatment response to zoledronic acid. (PubMed, J Pediatr Endocrinol Metab) - "LRP5-related disorders should be considered in patients with recurrent fractures and visual involvement. Zoledronate appears effective in improving bone density, reducing fracture frequency, and promoting vertebral remodeling, although further studies are required to determine optimal treatment duration."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Evolution of BMD and bone turnover markers after denosumab discontinuation with zoledronic acid in patients with spinal cord injury-induced osteoporosis (EULAR 2026) - No abstract available

Clinical • CNS Disorders • Orthopedics • Osteoporosis • Rheumatology

Inhibition of the immune checkpoint TIGIT enhances γδ T cell cytotoxicity against multiple myeloma in vitro (DKK 2026) - " PBMCs were isolated and stimulated with zoledronic acid and IL-2 over 15 days to achieve >90% γδ T cells...On day 14, γδ T cells were sorted based on TIGIT expression and co-cultured with the MM cell line OPM-2 and the bispecific antibody teclistamab, directed at BCMA and CD3...This experiment was repeated with the TIGIT inhibitor tiragolumab, which increased cytotoxicity in TIGIT+ γδ T cells, while TIGIT- cells showed only mild changes. Combining TIGIT inhibition with γδ T cell therapies may represent a promising strategy for improving cellular cancer immunotherapy."

IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • CD40LG • HAVCR2 • IL2 • IL2RA • LAG3 • NKG2D • PD-1 • PVR • TIGIT

A case of osteoporotic fracture leading to diagnosis of Klinefelter syndrome in a 76-year-old man. (PubMed, JCEM Case Rep) - "He received intravenous zoledronic acid, while androgen therapy was postponed pending urologic assessment. This case emphasizes that KS can remain undetected for decades and highlights the need to consider hypogonadism in men with unexplained bone loss. Early recognition facilitates appropriate treatment and long-term monitoring for associated systemic complications."

Journal • Endocrine Disorders • Genetic Disorders • Infertility • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Sexual Disorders

Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic mice. (PubMed, Front Endocrinol (Lausanne)) - "However, discontinued therapy after denosumab-zoledronate sequence, showed that the protective effects of zoledronate were not persistent. Our findings establish TgRANKL mice as a unique osteoporotic model for investigating the mechanisms driving denosumab rebound and testing sequential antiresorptive strategies."

Journal • Preclinical • Musculoskeletal Diseases • Obesity • Orthopedics • Osteoporosis • Rheumatology • TNFSF11

Characterization and therapeutic effects of an atorvastatin graphene oxide hydrogel on medication induced osteonecrosis of the jaws in female rats. (PubMed, Tissue Cell) - "A preclinical study was conducted in female Wistar rats using a model of MRONJ induced by Zoledronic Acid (ZA). It also reduced inflammation and enhanced blood vessel formation (+ 65.0%). No systemic alterations were observed."

Journal • Preclinical • Inflammation • Osteoporosis

Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia (clinicaltrials.gov) - P1/2 | N=2 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1/2 trial • Anemia • Genetic Disorders • Hematological Disorders

Zoledronic Acid Associated Anterior Uveitis - A Single Institutional Experience on Management and the Rechallenge. (PubMed, Ocul Immunol Inflamm) - "One patient switched to denosumab, and one declined further therapy. . ZAIU is an uncommon but reversible complication. Early recognition and timely treatment lead to excellent outcomes, and cautious rechallenge appears feasible in selected patients."

Journal • Ocular Inflammation • Oncology • Ophthalmology • Pain • Uveitis